Loading...
XJPX4506
Market cap1.40bUSD
Jan 23, Last price  
551.00JPY
1D
-2.30%
1Q
-7.08%
Jan 2017
-72.59%
Name

Sumitomo Pharma Co Ltd

Chart & Performance

D1W1MN
XJPX:4506 chart
P/E
—
P/S
0.70
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-7.29%
Revenues
314.56b
-43.38%
175,088,000,000245,784,000,000261,213,000,000263,992,000,000264,060,000,000296,295,000,000379,529,000,000350,384,000,000347,732,000,000387,709,000,000371,370,000,000403,205,000,000411,645,000,000466,838,000,000459,267,000,000482,732,000,000515,952,000,000560,035,000,000555,544,000,000314,558,000,000
Net income
-314.97b
L+322.71%
6,924,000,00015,377,000,00022,605,000,00025,591,000,00019,987,000,00020,958,000,00016,796,000,0008,629,000,00010,043,000,00020,060,000,00015,447,000,00024,697,000,00028,991,000,00053,448,000,00048,627,000,00040,753,000,00056,219,000,00056,413,000,000-74,512,000,000-314,969,000,000
CFO
-241.89b
L
15,523,000,0009,085,000,00037,872,000,00032,509,000,00026,295,000,00026,682,000,00055,041,000,00048,382,000,00049,914,000,00049,943,000,00030,251,000,00049,415,000,00021,624,000,00093,420,000,00048,711,000,00046,128,000,000135,601,000,00031,239,000,00011,937,000,000-241,893,000,000
Dividend
Mar 30, 20237 JPY/sh
Earnings
Jan 29, 2025

Profile

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
URL
https://www.sumitomo-pharma.co.jp/
IPO date
May 16, 1949
Employees
6,250
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
314,558,000
-43.38%
555,544,000
-0.80%
560,035,000
8.54%
Cost of revenue
636,919,000
743,950,000
538,891,000
Unusual Expense (Income)
NOPBT
(322,361,000)
(188,406,000)
21,144,000
NOPBT Margin
3.78%
Operating Taxes
(8,185,000)
48,794,000
42,361,000
Tax Rate
200.35%
NOPAT
(314,176,000)
(237,200,000)
(21,217,000)
Net income
(314,969,000)
322.71%
(74,512,000)
-232.08%
56,413,000
0.35%
Dividends
(2,792,000)
(11,125,000)
(11,126,000)
Dividend yield
1.77%
3.46%
2.32%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
285,517,000
90,588,000
25,085,000
Long-term debt
143,765,000
251,124,000
253,996,000
Deferred revenue
16,877,000
27,932,000
Other long-term liabilities
59,119,000
57,756,000
57,620,000
Net debt
231,678,000
33,661,000
(87,408,000)
Cash flow
Cash from operating activities
(241,893,000)
11,937,000
31,239,000
CAPEX
(15,730,000)
(12,742,000)
(13,494,000)
Cash from investing activities
33,036,000
52,419,000
(18,278,000)
Cash from financing activities
77,851,000
(146,817,000)
(21,426,000)
FCF
(325,075,000)
(224,365,000)
(27,995,000)
Balance
Cash
29,047,000
163,652,000
238,580,000
Long term investments
168,557,000
144,399,000
127,909,000
Excess cash
181,876,100
280,273,800
338,487,250
Stockholders' equity
156,818,000
710,181,000
1,210,179,000
Invested Capital
482,520,000
511,804,200
682,098,750
ROIC
ROCE
2.02%
EV
Common stock shares outstanding
397,292
397,292
397,293
Price
398.00
-50.86%
810.00
-32.95%
1,208.00
-37.31%
Market cap
158,122,154
-50.86%
321,806,520
-32.95%
479,929,944
-37.31%
EV
389,873,154
658,217,520
1,010,856,944
EBITDA
(284,596,000)
(147,143,000)
59,492,000
EV/EBITDA
16.99
Interest
4,277,000
3,159,000
3,050,000
Interest/NOPBT
14.42%